• In recent weeks, Merit Medical Systems faced a shift in Wall Street opinion when Wells Fargo downgraded its rating, prompting a period of sustained institutional selling despite no major operational changes.
• What stands out is that the company’s underlying operations and financial health remain solid, suggesting investor sentiment has moved more than the business fundamentals.
• We’ll now explore how Wells Fargo’s downgrade and the resulting sentiment shift may influence Merit Medical Systems’ existing investment narrative.

Find 48 companies with promising cash flow potential yet trading below their fair value.

Merit Medical Systems Investment Narrative Recap

To own Merit Medical Systems, you need to believe in the long term adoption of minimally invasive procedures and the company’s ability to grow through innovation and acquisitions, despite reimbursement and cost pressures. Wells Fargo’s downgrade and the recent share price weakness mainly affect sentiment rather than the core near term catalyst around WRAPSODY reimbursement progress, while existing risks such as China exposure and rising operating expenses remain more relevant to the business itself.

The most recent Q4 2025 and full year 2025 results showed continued revenue and earnings growth, with 2026 guidance pointing to further top line expansion, which helps frame the Wells Fargo downgrade against a backdrop of still growing operations. For investors, this contrast between softer market sentiment and ongoing business execution may sharpen the focus on whether current pricing already reflects known risks like delayed WRAPSODY outpatient reimbursement and higher spending on growth.

Yet while sentiment may swing quickly, the reimbursement delay for WRAPSODY and its impact on near term growth is something investors should be aware of...

Merit Medical Systems' narrative projects $1.8 billion revenue and $197.2 million earnings by 2028. This requires 7.0% yearly revenue growth and about a $78 million earnings increase from $119.1 million today.

Uncover how Merit Medical Systems' forecasts yield a $103.55 fair value, a 48% upside to its current price.

Exploring Other Perspectives

Two members of the Simply Wall St Community currently see fair value for Merit Medical Systems between US$81.94 and US$103.55, underscoring how far opinions can stretch. Set against the recent downgrade driven sentiment shift, this spread in views invites you to weigh WRAPSODY’s reimbursement delays and other firm specific risks through several contrasting lenses.

Explore 2 other fair value estimates on Merit Medical Systems - why the stock might be worth as much as 48% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Merit Medical Systems research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Merit Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merit Medical Systems' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.